Congress moves to prevent drug deaths through genetic testing and better alerts
H.R. 2471 — Right Drug Dose Now Act of 2025 · Filed by Eric Swalwell (D-CA) · 1 cosponsor · Introduced Mar 27, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Department of Health and Human Services to develop and update a national plan to prevent adverse drug events by incorporating pharmacogenetic testing—genetic tests that predict how a person's body will metabolize specific drugs. It requires the government to educate healthcare providers about pharmacogenetic testing, update electronic health record systems to flag dangerous drug-gene interactions before medications are prescribed, and modernize the FDA's adverse event reporting system to include genetic information. The bill benefits patients by potentially preventing harmful drug reactions and healthcare providers by giving them better tools to prescribe safely.
Why we flagged it
The bill's core mechanism is regulatory and educational—it mandates federal coordination on adverse drug event prevention and requires HHS to issue guidance and update systems. It is not a subsidy, tax provision, or industry carve-out; it is a straightforward public-health directive.
What the text implies
- Pharmacogenetic testing adoption may increase healthcare costs in the short term if insurers do not cover tests; however, long-term savings from prevented adverse events and hospitalizations likely offset this.
- The bill's emphasis on electronic health record integration may accelerate EHR vendors' development of pharmacogenomics modules, potentially creating competitive advantage for vendors with existing genetic-data infrastructure.
The full analysis lists 4 implications of this text.
Who stands to gain
genetic testing companies; electronic health record vendors; clinical laboratory networks